Simple jQuery Dropdowns

Browsing by Author Robert M. Paris

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 9 of 9
Issue DateTitleAuthor(s)
31-Mar-2005Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX® B/E prime-boost HIV-1 vaccine trial in ThailandChitraporn Karnasuta; Robert M. Paris; Josephine H. Cox; Sorachai Nitayaphan; Punnee Pitisuttithum; Prasert Thongcharoen; Arthur E. Brown; Sanjay Gurunathan; James Tartaglia; William L. Heyward; John G. McNeil; Deborah L. Birx; Mark S. De Souza; Armed Forces Research Institute of Medical Sciences, Thailand; U.S. Military HIV Research Program; Mahidol University; Sanofi Pasteur SA; Aventis Pasteur; VaxGen, Inc.
15-Apr-2013Extended evaluation of the virologic, immunologic, and clinical course of volunteers who acquired HIV-1 infection in a phase III vaccine trial of ALVAC-HIV and AIDSVAX B/ESupachai Rerks-Ngarm; Robert M. Paris; Supamit Chunsutthiwat; Nakorn Premsri; Chawetsan Namwat; Chureeratana Bowonwatanuwong; Shuying S. Li; Jaranit Kaewkungkal; Rapee Trichavaroj; Nampueng Churikanont; Mark S. De Souza; Charla Andrews; Donald Francis; Elizabeth Adams; Jorge Flores; Sanjay Gurunathan; Jim Tartaglia; Robert J. O'Connell; Chirapa Eamsila; Sorachai Nitayaphan; Viseth Ngauy; Prasert Thongcharoen; Prayura Kunasol; Nelson L. Michael; Merlin L. Robb; Peter B. Gilbert; Jerome H. Kim; Thailand Ministry of Public Health; US Military HIV Research Program; Chonburi Regional Hospital; Fred Hutchinson Cancer Research Center; Mahidol University; Armed Forces Research Institute of Medical Sciences, Thailand; Global Solutions in Infectious Diseases; National Institute of Allergy and Infectious Diseases; Sanofi Pasteur; Royal Thai Army
1-Mar-2005Functional variation of HIV-1 Rev Response Element in a longitudinally studied cohortAngsana Phuphuakrat; Robert M. Paris; Sorachai Nittayaphan; Suda Louisirirotchanakul; Prasert Auewarakul; Mahidol University; Armed Forces Research Institute of Medical Sciences, Thailand
1-Oct-2015HIV-1 infections with multiple founders are associated with higher viral loads than infections with single foundersHolly Janes; Joshua T. Herbeck; Sodsai Tovanabutra; Rasmi Thomas; Nicole Frahm; Ann Duerr; John Hural; Lawrence Corey; Steve G. Self; Susan P. Buchbinder; M. Juliana McElrath; Robert J. O'Connell; Robert M. Paris; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttihum; Jaranit Kaewkungwal; Merlin L. Robb; Nelson L. Michael; James I. Mullins; Jerome H. Kim; Peter B. Gilbert; Morgane Rolland; Fred Hutchinson Cancer Research Center; University of Washington, Seattle; Walter Reed Army Institute of Research; HJF; Armed Forces Research Institute of Medical Sciences, Thailand; Thailand Ministry of Public Health; Mahidol University
1-Nov-2015IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine RegimensNicos Karasavvas; Chitraporn Karnasuta; Hathairat Savadsuk; Sirinan Madnote; Dutsadee Inthawong; Somsak Chantakulkij; Surawach Rittiroongrad; Sorachai Nitayaphan; Punnee Pitisuttithum; Prasert Thongcharoen; Vinai Siriyanon; Charla A. Andrews; Susan W. Barnett; James Tartaglia; Faruk Sinangil; Donald P. Francis; Merlin L. Robb; Nelson L. Michael; Viseth Ngauy; Mark S. De Souza; Robert M. Paris; Jean Louis Excler; Jerome H. Kim; Robert J. O'Connell; Armed Forces Research Institute of Medical Sciences, Thailand; Mahidol University; Chiang Mai University; TECHNICAL RESOURCES INTERNATIONAL, INC.; NOVARTIS VACCINES AND DIAGNOSTICS, INC.; Sanofi Pasteur; Global Solutions for Infectious Diseases; Walter Reed Army Institute of Research; HJF; International Vaccine Institute, Seoul
1-Sep-2007A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01_AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boostPrasert Thongcharoen; Vinai Suriyanon; Robert M. Paris; Chirasak Khamboonruang; Mark S. De Souza; Silvia Ratto-Kim; Chitraporn Karnasuta; Victoria R. Polonis; Lynn Baglyos; Raphaelle El Habib; Sanjay Gurunathan; Susan Barnett; Arthur E. Brown; Deborah L. Birx; John G. McNeil; Jerome H. Kim; Faculty of Medicine, Siriraj Hospital, Mahidol University; Chiang Mai University; Armed Forces Research Institute of Medical Sciences, Thailand; HJF; Sanofi Pasteur; Sanofi Pasteur SA; Novartis Vaccines and Diagnostics, Inc.; US Army Medical Materiel Development Activity; Centers for Disease Control and Prevention; PATH Malaria Vaccine Initiative; Mahidol University
9-Dec-2010Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia ankara-HIV-1 vaccine candidateJeffrey R. Currier; Viseth Ngauy; Mark S. de Souza; Silvia Ratto-Kim; Josephine H. Cox; Victoria R. Polonis; Patricia Earl; Bernard Moss; Sheila Peel; Bonnie Slike; Somchai Sriplienchan; Prasert Thongcharoen; Robert M. Paris; Merlin L. Robb; Jerome Kim; Nelson L. Michael; Mary A. Marovich; US MIlitary HIV Research Program/Henry M. Jackson Foundation; Armed Forces Research Institute of Medical Sciences, Thailand; International AIDS Vaccine Initiative; National Institute of Allergy and Infectious Diseases; Mahidol University
1-Jul-2012Risk behaviour and time as covariates for efficacy of the HIV vaccine regimen ALVAC-HIV (vCP1521) and AIDSVAX B/E: A post-hoc analysis of the Thai phase 3 efficacy trial RV 144Merlin L. Robb; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Patricia Morgan; Michael Benenson; Robert M. Paris; Joseph Chiu; Elizabeth Adams; Donald Francis; Sanjay Gurunathan; Jim Tartaglia; Peter Gilbert; Don Stablein; Nelson L. Michael; Jerome H. Kim; Walter Reed Army Institute of Research; Thailand Ministry of Public Health; Armed Forces Research Institute of Medical Sciences, Thailand; Mahidol University; Biophics; Henry Jackson Foundation; Walter Reed National Military Medical Center; National Institute of Allergy and Infectious Diseases; Global Solutions for Infectious Diseases; Sanofi Pasteur; Fred Hutchinson Cancer Research Center; The EMMES Corporation; US Army Medical Materiel Development Activity
15-May-2012The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelopeMark S. De Souza; Silvia Ratto-Kim; Weerawan Chuenarom; Alexandra Schuetz; Somsak Chantakulkij; Bessara Nuntapinit; Anais Valencia-Micolta; Doris Thelian; Sorachai Nitayaphan; Punnee Pitisuttithum; Robert M. Paris; Jaranit Kaewkungwal; Nelson L. Michael; Supachai Rerks-Ngarm; Bonnie Mathieson; Mary Marovich; Jeffrey R. Currier; Jerome H. Kim; Supamit Chunsuttiwat; Nakorn Premsri; Chawetsan Namwat; Prayura Kunasol; Prasert Thongcharoen; Chirasak Khamboonruang; Valai Bussaratid; Wirach Maek-a-nantawat; Jittima Dhitavat; Pravan Suntharasamai; Swangjai Pungpak; Siriwan Vanijanonta; Jaranit Kaewkunwal; Amnat Khamsiriwatchara; Pawinee Jarujareet; Chirapa Easmila; Suchana Tabprasit; Viseth Ngauy; Robert Paris; Michael Benenson; Patricia Morgan; Arthur Brown; Mark De Souza; Rapee Trichavaroj; Nusara Thaitawat; Kanyasiri Kongnonkok; Boot Keawboon; Yuwadee Phuang-Ngern; Susan Mason; Sanjay Gurunathan; Jim Tartaglia; John G. McNeil; Robin Harkness; Claude Meric; Lynn Baglyos; Raphaelle El Habib; Don Francis; Carter Lee; Elizabeth Adams; Merlin L. Robb; Mark Milazzo; Amy Bolen; Beryl Wessner; Jeffrey Currier; Deborah L. Birx; Don Stablein; Terry Germanson; Len Dally; Jean Louis Excler; Jeffrey Berenberg; Armed Forces Research Institute of Medical Sciences, Thailand; Walter Reed Army Institute of Research; Mahidol University; Thailand Ministry of Public Health; National Institutes of Health, Bethesda; Sanofi Pasteur; Sanofi Pasteur; Global Solutions in Infectious Diseases; National Institute of Allergy and Infectious Diseases; U.S. Army Medical Research and Materiel Command; Centers for Disease Control and Prevention; The EMMES Corporation; International AIDS Vaccine Initiative; Tripler Regional Med Center